Drug Profile
ITX 5061
Alternative Names: ITX-5061Latest Information Update: 04 May 2018
Price :
$50
*
At a glance
- Originator Kemia
- Developer iTherX Pharmaceuticals
- Class Antivirals; Small molecules
- Mechanism of Action SCARB1 protein antagonists; Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hepatitis C
Most Recent Events
- 16 Apr 2018 iTherX Pharmaceuticals terminates a phase I trial due to financial reasons in Hepatitis C in USA (PO) (NCT01560468)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Hepatitis-C in Puerto Rico (PO)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Hepatitis-C in United Kingdom (PO)